Completed PHASE4 INTERVENTIONAL NCT00061438

A Study to Determine if Antibiotics Prevent Infection in the Pancreas of Patients Where Part of the Pancreas Has Died

A Multicentre, Randomised, Double-blind, Placebo-controlled, Study on the Use of Prophylactic Meropenem Therapy in Subjects With Severe Acute Necrotizing Pancreatitis

Sponsor: Pfizer

Conditions Pancreatitis, Acute Necrotizing

Interventions meropenem

Updated 6 times since 2017 Last updated: Aug 31, 2017 Started: Feb 28, 2003 Primary completion: Dec 31, 2004 Completion: Dec 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Pancreatitis, Acute Necrotizing, this trial is completed. The trial is conducted by Pfizer and has accumulated 6 data snapshots since 2003. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Sep 2017 — Jun 2018 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Sep 2017 [monthly]

Completed PHASE4

First recorded

Feb 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Boston, United States , Chicago, United States , Montreal, Canada , New York, United States , Newark, United States , San Francisco, United States , Seattle, United States , Tampa, United States , Toronto, Canada and 1 more location